BIG Breast International Group
We will find a cure for breast cancer through global research and collaboration.


26 July 2017

APHINITY: Call for Research Proposals

Following the APHINITY Translational Advisory Committee (TAC) and Steering Committee (SC) meetings and the public presentation of the primar…Read more

20 July 2017

ALTTO – Translational Research Proposals Call opened for Residual Biological Material

The (Neo)ALTTO Steering Committee decided to open a call for Translational Research Proposals using Residual Biological Material from the AL…Read more

10 July 2017

BIG’s Annual Report 2016 is now available!

The Breast International Group (BIG) is committed to providing clear and timely information about its research activities, fundraising and f…Read more

03 July 2017

BIG just appointed new Executive Board which went into effect on 1 July 2017

Brussels, 3 July 2017 – The Breast International Group (BIG), one of the largest international not-for-profit organisations for academic bre…Read more

29 June 2017

ALTTO & NeoALTTO – Research Proposals Call opened for access to Study Data

The (Neo)ALTTO Steering Committee decided to open a call for Research Proposals using Data Only from the ALTTO and NeoALTTO studies. The …Read more

26 June 2017

MINDACT poster session at ASCO annual meeting 2017

On 4 June 2017, the MINDACT study presented the chemotherapy randomisation results at the American Society of Clinical Oncology (ASCO) Annua…Read more

14 June 2017

ALTTO and NeoALTTO studies presented updated results at the ASCO Annual Meeting in Chicago

On 4 and 5 June 2017, both the ALTTO and NeoALTTO studies presented updated results at the American Society of Clinical Oncology (ASCO) Annu…Read more

09 June 2017

Meet the new BIG HQ staff members

Reflecting the global outreach of BIG, whose 56 academic Members Groups represent the largest international network dedicated to breast canc…Read more

06 June 2017

APHINITY study shows Roche’s Perjeta®-based regimen reduced the risk of invasive cancer returning compared to Herceptin® and chemotherapy in HER2-positive early breast cancer

•Phase III study confirms benefit of the Perjeta-based regimen over the current standard of care •The study was positive in the overall po…Read more

31 May 2017

The HERA trial (BIG 1-01): 11-year follow-up results published in The Lancet

Further to the main trial results that were presented and published in 2005, the final analysis of the HERA study was recently published in …Read more

24 May 2017

BIG trials to be highlighted at ASCO 2017

The annual ASCO meeting will be taking place from 2to 6 June 2017 and will gather over 30, 000 oncology professionals from all corners of th…Read more

05 April 2017

POSITIVE (IBCSG 48-14/BIG 8-13) – More than 100 patients already enrolled

The international and purely academic POSITIVE study has already recruited more than 100 patients from 113 activated hospitals and cancer ce…Read more

22 March 2017

LORELEI: recruitment finished ahead of schedule and results expected soon

The LORELEI study finished its recruitment three months ahead of schedule, enrolling a total of 334 patients from 103 hospitals worldwide. T…Read more

10 March 2017

Dr. Giuseppe Curigliano to receive the first “ESO Umberto Veronesi Memorial Award” during 15th St. Gallen International Breast Cancer Conference

Dr. Giuseppe Curigliano, a member of the Breast International Group (BIG), to receive the “ESO Umberto Veronesi Memorial Award” during 15th …Read more

« Previous123456...10Next »
Scroll to top

Contact us

Breast International Group (BIG)-aisbl Blvd de Waterloo 121 B-1000 Brussels | Belgium VAT BE 0468 176 240